GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 232 filers reported holding GENMAB A/S in Q4 2022. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,312 | -1.6% | 1,228 | +6.0% | 0.00% | 0.0% |
| Q2 2023 | $44,016 | +55.8% | 1,158 | +54.8% | 0.00% | 0.0% |
| Q1 2023 | $28,244 | -0.2% | 748 | +12.0% | 0.00% | 0.0% |
| Q4 2022 | $28,310 | -19.1% | 668 | -39.2% | 0.00% | -50.0% |
| Q3 2022 | $35,000 | +75.0% | 1,098 | +74.8% | 0.00% | +100.0% |
| Q2 2022 | $20,000 | -47.4% | 628 | -39.5% | 0.00% | -50.0% |
| Q1 2022 | $38,000 | -29.6% | 1,038 | -23.8% | 0.00% | 0.0% |
| Q4 2021 | $54,000 | -35.7% | 1,362 | -28.8% | 0.00% | -33.3% |
| Q3 2021 | $84,000 | +52.7% | 1,912 | +41.4% | 0.00% | +50.0% |
| Q2 2021 | $55,000 | +66.7% | 1,352 | +36.3% | 0.00% | 0.0% |
| Q1 2021 | $33,000 | -23.3% | 992 | -5.7% | 0.00% | 0.0% |
| Q4 2020 | $43,000 | +19.4% | 1,052 | +6.0% | 0.00% | 0.0% |
| Q3 2020 | $36,000 | +50.0% | 992 | +35.5% | 0.00% | 0.0% |
| Q2 2020 | $24,000 | +500.0% | 732 | +229.7% | 0.00% | – |
| Q1 2020 | $4,000 | -20.0% | 222 | -4.3% | 0.00% | – |
| Q4 2019 | $5,000 | – | 232 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |